Multimodal approach to postoperative pain control in patients undergoing rotator cuff repair.
Chul-Hyun Cho, Kwang-Soon Song, Byung-Woo Min...
https://pubmed.ncbi.nlm.nih.gov/20957469/Actively Recruiting
Led by Henry Ford Health System · Updated on 2026-08-20
150
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating pain control methods after total knee replacement surgery for people with osteoarthritis of the knee. The study compares a new long-acting medication called Zynrelef with two common pain treatments a nerve block called the adductor canal block and a standard injection into the knee during surgery. The goal is to find pain control options that may reduce or eliminate the need for opioid pain medicines, which can have side effects and risks. Participants will be randomly assigned to one of three groups the standard periarticular injection group receiving a mix of ropivacaine, epinephrine, and ketorolac during surgery the adductor canal block group receiving a nerve block before surgery or the Zynrelef group receiving extended-release bupivacaine injected into the knee before closure along with a smaller dose of the standard injection. All participants will receive the same medicines before and after surgery and follow the same physical therapy and follow-up schedules. During the study, participants will record their pain levels and pain medicine use for several weeks after surgery. Researchers will measure postoperative pain scores using a numeric rating scale for the first five days after surgery and monitor outcomes such as emergency visits, readmissions, complications, and mortality for 90 days. Participants will have follow-up visits and assessments as part of routine care, and the study will monitor safety and recovery progress over the months following surgery.
CONDITIONS
Novel Extended-Release Bupivacaine Polymer for Sustained Pain Relief Following Total Knee Arthroplasty
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Henry Ford Health System
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Bupivacaine-Meloxicam (ER polymer + abbreviated periarticular injection) | Standard Periarticular Injection | Adductor Canal Block |
|---|---|---|---|
| What it is | An extended-release bupivacaine-meloxicam polymer injected into the knee joint space before wound closure, combined with a reduced-dose periarticular injection (PAI). | A standard periarticular injection of local anesthetic (ropivacaine), epinephrine, and ketorolac administered around the knee joint during surgery. | An adductor canal nerve block (ACB) performed before surgery by anesthesia, sometimes with an additional injection to the back of the knee, using ropivacaine. |
| Role in trial | Investigational strategy for sustained pain relief after knee replacement. | Active comparator using standard multimodal PAI for pain management. | Active comparator using perioperative nerve block for pain control. |
| Primary use | To provide extended pain relief and reduce opioid use after total knee replacement surgery. | To manage postoperative pain and support recovery following knee replacement. | To control pain during and after surgery for improved function following knee arthroplasty. |
| How it is given or performed | The extended-release bupivacaine-meloxicam formulation is injected into the knee during surgery before closing the incision, with an additional reduced periarticular injection. | A mixture containing ropivacaine, epinephrine, and ketorolac is injected into the knee tissues by the surgeon during the operation. | A nerve block using ropivacaine is performed by anesthesia prior to surgery, sometimes combined with additional local injection for the back of the knee. |
| Evidence status | Early trials suggest reduced pain and opioid use after knee replacement, but results in larger studies are awaited. | Serves as a foundation of modern pain protocols; multiple studies show benefit for postoperative pain and function. | Frequently used for minimizing immediate postoperative pain and enabling earlier mobilization. |
| Important limitations | Long-term effectiveness and comparative tolerability versus established strategies remain under evaluation. Access outside clinical trials may be limited. | Effectiveness may vary with technique and patient factors; duration of pain control is generally under 24 hours. | Duration of pain relief may be limited; block must be performed by an anesthesia provider and carries standard procedural risks. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of surgery
Participants receive one of three pain control methods during or before their total knee replacement surgery: a standard injection, the Zynrelef extended-release injection, or a nerve block. All receive the same pre- and postoperative medicines and physical therapy.
Surgery day and follow-up visits
Duration - Up to 90 days post-surgery
Participants record pain scores and pain medicine use for several weeks after surgery. Researchers monitor recovery and safety outcomes including hospital visits and complications for 90 days.
Regular follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Chul-Hyun Cho, Kwang-Soon Song, Byung-Woo Min...
https://pubmed.ncbi.nlm.nih.gov/20957469/Paul F Lachiewicz, Gwo-Chin Lee, Richard A Pollak...
https://pubmed.ncbi.nlm.nih.gov/32561266/Gwo-Chin Lee, Richard Berkowitz, Scott Hacker...
https://pubmed.ncbi.nlm.nih.gov/35688442/Vasilios Moutzouros, Toufic R Jildeh, Lafi S Khalil...
https://pubmed.ncbi.nlm.nih.gov/32353620/Pamela A Chia, Maxime Cannesson, Christine C Myo Bui
https://pubmed.ncbi.nlm.nih.gov/32530891/Rebecca E Scully, Andrew J Schoenfeld, Wei Jiang...
https://pubmed.ncbi.nlm.nih.gov/28973092/Deren T Bagsby, Phillip H Ireland, R Michael Meneghini
https://pubmed.ncbi.nlm.nih.gov/24793570/Charbel El-Kefraoui, Ghadeer Olleik, Marc-Aurele Chay...
https://pubmed.ncbi.nlm.nih.gov/32014880/Julio F Fiore, Ghadeer Olleik, Charbel El-Kefraoui...
https://pubmed.ncbi.nlm.nih.gov/31563269/Eugene Viscusi, Joseph S Gimbel, Richard A Pollack...
https://pubmed.ncbi.nlm.nih.gov/31113830/Henry Ford Health System
Lead Sponsor